Claims
- 1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 143, 145, 147, 149, 151, 167, 203, 217, 231, 233, 51, 65, 67, 68, 100, and 153.
- 2. A vector which contains the nucleic acid molecule of claim 1.
- 3. A host cell which contains the nucleic acid molecule of claim 1.
- 4. A method of assessing whether a patient is afflicted with cervical cancer, the method comprising comparing:
a) the level of expression of a marker in a patient sample, wherein the marker is selected from Table 1; and b) the normal level of expression of the marker in a control non-cervical cancer sample,
wherein a significant increase in the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with cervical cancer.
- 5. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 143, 145, 147, 149, 151, 167, 203, 217, 231, and 233.
- 6. An antibody which selectively binds to the polypeptide of claim 5.
- 7. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 144, 146, 148, 150, 152, 168, 204, 218, 232, and 234.
- 8. An antibody which selectively binds to the polypeptide of claim 7.
RELATED APPLICATIONS
[0001] The present application claims priority to U.S. provisional patent application serial No. 60/298,159, filed on Jun. 13, 2001, U.S. provisional patent application serial No. 60/298,155, filed on Jun. 13, 2001, and U.S. provisional patent application serial No. 60/335,936, filed on Nov. 14, 2001, all of which are expressly incorporated by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60298159 |
Jun 2001 |
US |
|
60298155 |
Jun 2001 |
US |
|
60335936 |
Nov 2001 |
US |